Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668906 | 0.82 | LIPG (0.44) | DGAT1HIF1APRMT5WDR77LPL | |
| SCHEMBL25421822 | 0.78 | CSF1R (0.43) | DGAT1PRMT5WDR77LPLLIPG | |
| SCHEMBL25035049 | 0.77 | HIF1A (0.43) | DGAT1HIF1ALPLLIPGCSF1R | |
| SCHEMBL20074527 | 0.76 | LMNA (0.43) | DGAT1HIF1APRMT5WDR77GSK3A | |
| SCHEMBL29727178 | 0.76 | LMNA (0.43) | DGAT1HIF1APRMT5WDR77GSK3A | |
| SCHEMBL2382334 | 0.75 | PDE4B (0.48) | DGAT1HIF1APRMT5WDR77LPL | |
| SCHEMBL2281668 | 0.75 | ALDH1A1 (0.51) | DGAT1HIF1ALPLLIPGCA1 | |
| SCHEMBL2697552 | 0.75 | CA1 (0.53) | DGAT1HIF1ALPLLIPGCA1 | |
| SCHEMBL3461872 | 0.75 | MEN1 (0.47) | DGAT1HIF1ALPLLIPGCA1 | |
| SCHEMBL209359 | 0.75 | HIF1A (0.43) | DGAT1HIF1APRMT5WDR77LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-116059394-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-109562170-B | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司（US） | 2023-01-13 | — | — | CN | disclosed |
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3468596-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468996-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3458479-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-3230282-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | AbbVie Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | DGAT1 943/4885HIF1A 1639/4885PRMT5 1773/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | DGAT1 1143/4885HIF1A 1510/4885PRMT5 2489/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | DGAT1 3452/4885HIF1A 3028/4885PRMT5 324/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | DGAT1 2068/4885HIF1A 3864/4885PRMT5 2832/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | DGAT1 2068/4885HIF1A 3864/4885PRMT5 2832/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | DGAT1 2068/4885HIF1A 3864/4885PRMT5 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.